FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:207-208 July 14, 2005 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Patients with lung cancer who respond to gefitinib have been reported to have somatic mutations consisting of deletions in exon 19 and the L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) gene.¹ In addition, a second mutation (T790M) in exon 20 is also associated with acquired resistance to gefitinib in initially gefitinib-sensitive patients.^2,3 We describe a patient with gefitinib-resistant lung adenocarcinoma harboring both T790M and L858R at diagnosis.

A 55-year-old woman who had never smoked presented with blurred vision and slurred speech. Magnetic resonance imaging of the brain disclosed a rim-enhanced . . . [Full Text of this Article]

This article has been cited by other articles:

• Sequist, L. V., Joshi, V. A., Janne, P. A., Muzikansky, A., Fidias, P., Meyerson, M., Haber, D. A., Kucherlapati, R., Johnson, B. E., Lynch, T. J. (2007). Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.. The Oncologist 12: 90-98 [Abstract] [Full Text]  
• Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., Soria, J.-C. (2006). Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study.. Clin. Cancer Res. 12: 6049-6055 [Abstract] [Full Text]  
• Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.. Clin. Cancer Res. 12: 5764-5769 [Abstract] [Full Text]  
• Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., Kiura, K., Shimizu, N., Date, H. (2006). Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non-Small Cell Lung Cancer. Cancer Res. 66: 7854-7858 [Abstract] [Full Text]  
• von Bubnoff, N., Manley, P. W., Mestan, J., Sanger, J., Peschel, C., Duyster, J. (2006). Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328-1333 [Abstract] [Full Text]  
• Van Schaeybroeck, S., Kyula, J., Kelly, D. M., Karaiskou-McCaul, A., Stokesberry, S. A., Van Cutsem, E., Longley, D. B., Johnston, P. G. (2006). Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Molecular Cancer Therapeutics 5: 1154-1165 [Abstract] [Full Text]